Finance

Lists
ATYR:NASDAQ
aTyr Pharma Inc
$0.53
+0.96%
(+0.0051) 1D
$0.54
+1.85% (+0.0099)
After hours
Closed: Aug 11, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ATYR...
Open
$0.54
High
$0.54
Low
$0.51
Mkt. cap
52.27M
Avg. vol.
1.23M
Volume
99.00
52-wk high
$6.50
52-wk low
$0.40
EPS
-$0.62
Beta
0.54
Shares outstanding
98.09M
No. of employees
59
Open
$0.54
High
$0.54
Low
$0.51
Mkt. cap
52.27M
Avg. vol.
1.23M
Volume
99.00
52-wk high
$6.50
52-wk low
$0.40
EPS
-$0.62
Beta
0.54
Shares outstanding
98.09M
No. of employees
59
News stories
From web sources and news partners
Profile
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients. The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
About aTyr Pharma Inc
CEO-
Employees59
FoundedJan 1, 2005
Headquarters-
SectorBiotechnology
Websiteatyrpharma.com
Analyst ratings
Based on 6 analysts giving stock ratings to ATYR in the past 3 months
Buy
Buy
2
Hold
4
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for ATYR in the last 3 months.
Highest
Current $0.53
$7.00 (+1,210.86%)
Average
$3.13 (+486.14%)
Lowest
$1.00 (+87.27%)
Analyst
Recommendation
Action
Price target
Projected
Date
Derek Archila
Wells Fargo
Hold
Reiterated
$1.00
+87.3%
08/10/2026
Boris Peaker
JonesTrading
Hold
Reiterated
-
-
08/10/2026
Brian Abrahams
RBC Capital
Hold
Maintained
$1.00
+87.3%
08/09/2026
Joseph Pantginis
H.C. Wainwright
Hold
Maintained
-
-
08/10/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$7.00
+1,210.9%
07/16/2026
Ilya Zubkov
Freedom Capital Markets
Buy
Upgraded
$3.50
+555.4%
05/20/2026
Soumit Roy
JonesTrading
Hold
Maintained
-
-
04/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
190.00K
-
-
-
Cost of goods sold
22.13M
10.89M
7.32M
-
Cost of revenue
22.13M
10.89M
7.32M
-
Research and development expenses
-
-
-
6.75M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.80M
3.90M
4.12M
4.13M
Operating expense
4.80M
3.90M
4.12M
10.88M
Total operating expenses
26.94M
14.80M
11.44M
10.88M
Operating income
-26.74M
-14.80M
-11.44M
-10.88M
Other non operating income
999.00K
832.00K
644.00K
571.00K
EBT including unusual items
-25.75M
-13.96M
-10.79M
-10.31M
EBT excluding unusual items
-25.75M
-13.96M
-10.79M
-10.31M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-25.74M
-13.96M
-10.79M
-10.31M
Net profit margin
-13,549.47%
-
-
-
Earnings per share
-0.26
-0.14
-0.11
-0.11
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-26.58M
-14.63M
-11.27M
-10.72M
Gain or loss from assets sale
-
-12.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps